Midtrimester pregnancy termination for fetal malformations. use of intravaginal prostaglandin E2
Hagar, D.L.; Valley, M.T.; Rayburn, W.F.; Carey, J.C.
Journal of Reproductive Medicine 42(8): 497-500
1997
ISSN/ISBN: 0024-7758 PMID: 9284011 Document Number: 479466
The capability to identify major fetal malformations in the middle trimester of pregnancy has increased the number of requests for late pregnancy termination. This retrospective study compared the use of prostaglandin E2 (PGE2) suppositories in 38 pregnancies undergoing induction of labor before 23 weeks of gestation after confirmation of 1 or more major fetal malformations and a control group of 27 pregnancies undergoing induction because of fetal death. Both groups were identified through a perinatal database of all pregnancies delivered at an Oklahoma City, Oklahoma, hospital in a 30-month period during 1992-94. The most frequent fetal malformations were cystic hygroma, spina bifida, hydrocephalus, and anencephaly. The median number of 20 mg PGE2 doses required was greater in the fetal malformation group (4, range 1-10) than the fetal death group (3, range 1-6). The total dosage was also greater for the malformation group (77.5 +or- 38.5 mg) than for the fetal death group (61.8 +or- 37.8 mg). Mean time until delivery was 2 hours less in the fetal death group, but the percentage of women delivering within 24 hours was similar in both groups (81.6% in the fetal malformation group and 85.2% in the fetal death group). All malformed fetuses were delivered stillborn. The frequencies of maternal side effects such as fever, vomiting, and diarrhea were somewhat greater in the fetal malformation group, presumably because of the higher dosage of PGE2. Although women undergoing second-trimester PGE2-induced labor for fetal malformations should be counseled that labor may last longer and a higher drug dosage may be required than in pregnancies complicated by fetal death, the method seems to be highly effective in both situations.